In this interview we talk to Jose Arribas about the challenges facing antiretroviral treatments and the future of long-acting formulations for HIV. What new drugs might we have for this disease in the coming years? Read our interview to find out more.
In this interview we speak to David Padley from the National Institute for Biological Standards and Control about his recent poster ‘Point-of-Care testing for HIV: specialist quality control materials are a necessity’, presented at ECCMID 2019.
Early antiretroviral treatment in people with HIV infection could allow the generation of more functional and persistent CD8 T cell responses. The results, which suggest a long-term immune memory, could have implications for HIV vaccine development.
Delivering HIV vaccines via slow-release methods has enhanced the protective immune response in preclinical models, according to new research.
Healthcare practitioners have split opinions on whether primary care doctors or other providers should take the lead on prescribing PrEP for HIV prevention, according to new research.
New research describes the use of small-molecule CD4 mimetic compounds that force HIV to undergo conformational changes, exposing normally hidden parts of the envelope and potential new targets.
Take a look behind the scenes of a recent Future Virology review entitled ‘An update on the management of hepatitis C virus and human immunodeficiency virus coinfection’, as we ask the authors about their inspiration and the future of this field.
Take a look at this month’s industry headlines including news on Sanofi’s Dengvaxia® vaccine from the USA and the Philippines, clinical trial results for RSV vaccines and HIV injectables and new acquisitions for Merck.
Find out more about the headlines from the Conference on Retroviruses and Opportunistic Infections 2019 (CROI) in our round-up of conference news.
A second individual has achieved sustained remission from HIV-1 after ceasing antiretroviral treatment, according to researchers from University College London. Following a hematopoietic stem cell transplant and chemotherapy the patient has had undetectable viral loads for 18 months.